Patent: 9,522,956
✉ Email this page to a colleague
Summary for Patent: 9,522,956
Title: | Combination therapy using anti-EGFR and anti-HER2 antibodies |
Abstract: | The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody \"trastuzumab\" (HERCEPTIN.RTM.) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody \"matuzumab\" (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer. |
Inventor(s): | Gillies; Stephen D. (Carlisle, MA), Azria; David (Mauguio, FR), Larbouret; Christel (Montpellier, FR), Pelegrin; Andre (Montpellier, FR) |
Assignee: | L\'Institut National de la Sante et de la Recherche Medicale (Paris, FR) |
Application Number: | 14/536,854 |
Patent Claims: | see list of patent claims |
Details for Patent 9,522,956
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2026-01-04 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2026-01-04 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2026-01-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |